Pacific Biosciences of California, Inc. logo

Pacific Biosciences of California, Inc.

PACB

NASDAQHealthcareMedical - Devices

Regular session

$1.2901

−$0.0599 · -4.44%

Aug 24, 10:13 AM ETData delayed

PACB company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

57

Fair Value

Momentum

48

Neutral

Sentiment

43

Mixed

Risk resilience

23

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Mark Van Oene
Listed since
Oct 27, 2010
Employees
485

Market position

Day range

Current $1.2901

52-week range

Current $1.2901

Open
$1.35
Previous close
$1.35
Volume
929.25K
0.14× average
Average volume
6.5M
Average daily volume
Market cap
400.71M USD
Beta
2.32
Market reference 1
50-day average
$1.3982
-7.73% below average
200-day average
$1.6553
-22.06% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-3×
P/B (TTM)
-12.07×
P/S (TTM)
2.52×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
35.97%
Operating margin
-102.05%
Net margin
-82.49%

Financial health

Debt / equity
-21.26×
Altman Z-score
-4.71
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends84%-73%-230%-388%Gross margin, FY2021: 45.10%Gross margin, FY2022: 38.22%Gross margin, FY2023: 26.32%Gross margin, FY2024: 24.21%Gross margin, FY2025: 31.67%Operating margin, FY2021: -161.24%Operating margin, FY2022: -239.43%Operating margin, FY2023: -166.80%Operating margin, FY2024: -307.97%Operating margin, FY2025: -348.46%Net margin, FY2021: -138.85%Net margin, FY2022: -244.92%Net margin, FY2023: -152.97%Net margin, FY2024: -201.18%Net margin, FY2025: -341.47%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 45.10%. Gross margin FY2022 38.22%. Gross margin FY2023 26.32%. Gross margin FY2024 24.21%. Gross margin FY2025 31.67%. Operating margin FY2021 -161.24%. Operating margin FY2022 -239.43%. Operating margin FY2023 -166.80%. Operating margin FY2024 -307.97%. Operating margin FY2025 -348.46%. Net margin FY2021 -138.85%. Net margin FY2022 -244.92%. Net margin FY2023 -152.97%. Net margin FY2024 -201.18%. Net margin FY2025 -341.47%.

Income trends

Revenue

160.01M USD+3.89%

Operating income

−557.56M USD-17.55%

Net income

−546.38M USD-76.34%
Income trends across reported periods276.33M USD−26.9M USD−330.14M USD−633.37M USDRevenue, FY2021: 130.51M USDRevenue, FY2022: 128.3M USDRevenue, FY2023: 200.52M USDRevenue, FY2024: 154.01M USDRevenue, FY2025: 160.01M USDOperating income, FY2021: −210.44M USDOperating income, FY2022: −307.2M USDOperating income, FY2023: −334.47M USDOperating income, FY2024: −474.31M USDOperating income, FY2025: −557.56M USDNet income, FY2021: −181.22M USDNet income, FY2022: −314.25M USDNet income, FY2023: −306.74M USDNet income, FY2024: −309.85M USDNet income, FY2025: −546.38M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 130.51M USD. Revenue FY2022 128.3M USD. Revenue FY2023 200.52M USD. Revenue FY2024 154.01M USD. Revenue FY2025 160.01M USD. Operating income FY2021 −210.44M USD. Operating income FY2022 −307.2M USD. Operating income FY2023 −334.47M USD. Operating income FY2024 −474.31M USD. Operating income FY2025 −557.56M USD. Net income FY2021 −181.22M USD. Net income FY2022 −314.25M USD. Net income FY2023 −306.74M USD. Net income FY2024 −309.85M USD. Net income FY2025 −546.38M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue160.01M USD154.01M USD200.52M USD128.3M USD130.51M USD
Cost of goods sold109.33M USD116.73M USD147.74M USD79.27M USD71.65M USD
Gross profit50.67M USD37.28M USD52.78M USD49.04M USD58.86M USD
Research and development97.31M USD134.92M USD187.17M USD193M USD112.9M USD
Selling, general, and administrative141.49M USD175.02M USD169.82M USD160.85M USD124.12M USD
Operating expenses608.24M USD511.6M USD387.25M USD356.23M USD269.3M USD
Interest expense6.95M USD13.41M USD14.34M USD14.69M USD12.53M USD
Depreciation and amortization504.91M USD53.35M USD32.69M USD17.32M USD11.59M USD
Operating income−557.56M USD−474.31M USD−334.47M USD−307.2M USD−210.44M USD
Net income−546.38M USD−309.85M USD−306.74M USD−314.25M USD−181.22M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-1.82
FY2025
Latest fiscal-year revenue
160.01M USD
FY2025 · +3.89% year over year
Next fiscal-year EPS consensus
-0.453
FY2026 · 3 analysts
Next fiscal-year revenue consensus
158.27M USD
FY2026 · 4 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend-0.12-0.74-1.36-1.97FY21FY22FY23FY24FY25FY26FY27FY28

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend230.43M193.29M156.16M119.02MFY21FY22FY23FY24FY25FY26FY27FY28

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

12 institutions

PACB news

PACB peers

ETFs holding PACB

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research PACB

research.disclaimer